ATE491723T1 - Neue verbindungen mit gemischter amylin aktivität - Google Patents

Neue verbindungen mit gemischter amylin aktivität

Info

Publication number
ATE491723T1
ATE491723T1 AT99906782T AT99906782T ATE491723T1 AT E491723 T1 ATE491723 T1 AT E491723T1 AT 99906782 T AT99906782 T AT 99906782T AT 99906782 T AT99906782 T AT 99906782T AT E491723 T1 ATE491723 T1 AT E491723T1
Authority
AT
Austria
Prior art keywords
treating
diabetes
amylin
compounds
type
Prior art date
Application number
AT99906782T
Other languages
English (en)
Inventor
Nigel Beeley
Kathryn Prickett
Kevin Beaumont
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE491723T1 publication Critical patent/ATE491723T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99906782T 1998-02-13 1999-02-05 Neue verbindungen mit gemischter amylin aktivität ATE491723T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7474698P 1998-02-13 1998-02-13
PCT/US1999/002603 WO1999040928A1 (en) 1998-02-13 1999-02-05 Novel mixed amylin activity compounds

Publications (1)

Publication Number Publication Date
ATE491723T1 true ATE491723T1 (de) 2011-01-15

Family

ID=22121450

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99906782T ATE491723T1 (de) 1998-02-13 1999-02-05 Neue verbindungen mit gemischter amylin aktivität

Country Status (8)

Country Link
EP (1) EP1053001B1 (de)
JP (1) JP4372345B2 (de)
AT (1) ATE491723T1 (de)
AU (1) AU766653B2 (de)
CA (1) CA2320962C (de)
DE (1) DE69943039D1 (de)
ES (1) ES2356595T3 (de)
WO (1) WO1999040928A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024727A2 (en) * 2000-09-19 2002-03-28 University Of Toronto New inhibitors of iapp fibril formation and uses thereof
EP1349563B1 (de) 2000-12-14 2009-12-02 Amylin Pharmaceuticals, Inc. Peptid pyy[3-36] zur behandlung von stoffwechselkrankheiten
CN1617737A (zh) * 2001-11-26 2005-05-18 普罗特米克斯公司 用于使哺乳动物组织中的脂质水平正常化的组合物和方法
US20070275877A1 (en) * 2003-08-29 2007-11-29 Amylin Pharmaceuticals, Inc. Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
WO2006083254A1 (en) * 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
AU2012266269B2 (en) 2011-06-10 2017-04-06 Novo Nordisk A/S Polypeptides
CN104395338B (zh) * 2012-04-19 2019-05-10 诺和诺德股份有限公司 人胰岛淀粉样多肽类似物
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
US20230082544A1 (en) 2020-02-18 2023-03-16 Novo Nordisk A/S Pharmaceutical formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8602950A (nl) 1985-12-04 1987-07-01 Sandoz Ag Calcitonine-derivaten en werkwijzen voor het bereiden van deze derivaten en van farmaceutische preparaten die ze bevatten.
DE3640042A1 (de) * 1985-12-04 1987-06-11 Sandoz Ag Neue calcitoninderivate
HU906341D0 (en) * 1986-10-13 1991-04-29 Sandoz Ag Process for producing peptonic derivatives modified with sugar and pharmaceutical preparatives containing these compounds as active substance
GB2218102B (en) 1988-04-08 1992-09-16 Sandoz Ltd Calcitonin peptide derivatives
US5321008A (en) 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5580953A (en) 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
DE69230041T2 (de) 1991-11-19 2000-01-05 Peptech (Uk) Ltd., London Muramylverbindungen zur behandlung von septischem schock
WO1993014408A1 (en) * 1992-01-14 1993-07-22 Amylin Pharmaceuticals, Inc. Myotonin receptors and screening methods
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
US5625032A (en) 1993-07-21 1997-04-29 Amylin Pharmaceuticals, Inc. Selective amylin antagonist peptides and uses therefor
US6114304A (en) * 1993-09-07 2000-09-05 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility

Also Published As

Publication number Publication date
JP2002522355A (ja) 2002-07-23
EP1053001A1 (de) 2000-11-22
AU2661299A (en) 1999-08-30
AU766653B2 (en) 2003-10-23
CA2320962C (en) 2011-04-19
JP4372345B2 (ja) 2009-11-25
CA2320962A1 (en) 1999-08-19
WO1999040928A1 (en) 1999-08-19
DE69943039D1 (de) 2011-01-27
EP1053001B1 (de) 2010-12-15
ES2356595T3 (es) 2011-04-11
EP1053001A4 (de) 2006-01-04

Similar Documents

Publication Publication Date Title
DE69935229D1 (de) Neue antidiabetische peptide
Urva et al. The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists
DE69943039D1 (de) Neue verbindungen mit gemischter amylin aktivität
FI952536A (fi) Glukagonia muistuttavia insulinotrooppisia komplekseja, koostumuksia ja menetelmiä
IL144703A0 (en) Methods and reagents for treating glucose metabolic disorders
BG104060A (en) Diabetes treatment with thiazolyidindion and methformine
NO20010982L (no) Fremgangsmåte for å administrere insulinotropiske peptider
MX9201110A (es) Composicion para el tratamiento de la diabetes mellitus, la hypoglicemia y de otros padecimientos relacionados.
ATE273996T1 (de) Zusammensetzung zur therapie von diabetes mellitus und fettsucht
BRPI0606727A (pt) terapia de combinação para o tratamento de diabetes e condições relacionadas com ele e para o tratamento de condições melhoradas através de aumento no nìvel de glp-1 no sangue
CY1106971T1 (el) Συνεργητικη χρηση θειαζολιδινοδιονων με πεπτιδιο-1 που ομοιαζει με γλυκογονο και αγωνιστες αυτου για να θεραπευεται μη-ινσουλινο εξαρτωμενος διαβητης
UA92451C2 (en) Polyethelene glycol link glp-1 compounds
CA2373266A1 (en) Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
CY1112398T1 (el) Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1
EP1145717A3 (de) Synergistische Wirkung von einem Sulfonylharnstoff und/oder einem nicht Sulfonylharnstoff K-ATP Kanalblocker und einem cAMP-Phosphodiestrerase Typ 3 Inhibitor
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
WO2006096565A3 (en) Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
BR0314799A (pt) Controle glicêmico aperfeiçoado para pré-diabetes e/ou diabetes do tipo ii usando ácido docosahexaenóico
NO20015932D0 (no) Fremgangsmåte til å behandle diabetes
WO2005070444A3 (en) Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
WO2005002612A8 (en) Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus and insulin resistance
Pieber et al. Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 2 diabetes
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
BRPI0506793A (pt) métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
TW200630085A (en) Agents and methods for administration to the central nervous system

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties